Does paricalcitol reduce proteinuria in patients with chronic kidney disease?

被引：0
|
作者：
Yoshiki Nishizawa
Tetsuo Shoji
机构：
[1] Professor of Medicine,Chair of the Department of Metabolism
[2] Endocrinology and Molecular Medicine,Department of Metabolism
[3] Dean of Osaka City University Graduate School of Medicine,undefined
[4] Endocrinology and Molecular Medicine at Osaka City University Graduate School of Medicine,undefined
来源：
Nature Clinical Practice Nephrology | 2006年 / 2卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：352 / 353
页数：1
相关论文
共 50 条
  • [1] Does paricalcitol reduce proteinuria in patients with chronic kidney disease? Commentary
    Nishizawa, Yoshiki
    Shoji, Tetsuo
    [J]. NATURE CLINICAL PRACTICE NEPHROLOGY, 2006, 2 (07): : 352 - 353
  • [2] Proteinuria and Albuminuria During and After Paricalcitol Treatment in Chronic Kidney Disease Patients
    Ekart, Robert
    Bevc, Sebastjan
    Hojs, Radovan
    Hojs, Nina
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (06): : 761 - 768
  • [3] Paricalcitol Reduces Proteinuria in Non-Dialysis Chronic Kidney Disease Patients
    Hojs, Nina
    Bevc, Sebastjan
    Balon, Breda Pecovnik
    Hojs, Radovan
    Ekart, Robert
    [J]. THERAPEUTIC APHERESIS AND DIALYSIS, 2013, 17 (04) : 368 - 372
  • [4] Safety and tolerability of paricalcitol in patients with chronic kidney disease
    Dyer, Christopher A.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2013, 12 (05) : 717 - 728
  • [5] Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease
    de Boer, Ian H.
    Sachs, Michael
    Hoofnagle, Andrew N.
    Utzschneider, Kristina M.
    Kahn, Steven E.
    Kestenbaum, Bryan
    Himmelfarb, Jonathan
    [J]. KIDNEY INTERNATIONAL, 2013, 83 (02) : 323 - 330
  • [6] THE USE OF PCSK9 INHIBITORS COULD REDUCE PROTEINURIA IN CHRONIC KIDNEY DISEASE PATIENTS
    Munoz Ramos, Patricia
    Gil Giraldo, Leydy Yohana
    Reque, Javier
    Quiroga, Borja
    Chiva, Vicente Alvarez
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 485 - 485
  • [7] ALBUMINURIA DURING AND AFTER PARICALCITOL TREATMENT IN CHRONIC KIDNEY DISEASE PATIENTS
    Ekart, Robert
    Hojs, Nina
    Bevc, Sebastjan
    Hojs, Radovan
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 376 - 376
  • [8] Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease
    Han, Tianzhao
    Rong, Gong
    Quan, Dayong
    Shu, Ying
    Liang, Zhu
    She, Ninglan
    Liu, Manli
    Yang, Bing
    Cheng, Gong
    Lv, Yongman
    Stern, Leonard
    [J]. BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [9] Spironolactone reduces proteinuria in patients with chronic kidney disease
    Bianchi, S
    Bigazzi, R
    Batini, V
    Campese, VM
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V71 - V72
  • [10] SPIRONOLACTONE REDUCES PROTEINURIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE
    Batini, Valentina
    Bianchi, Stefano
    Bigazzi, Roberto
    Campese, Vito M.
    [J]. NEPHROLOGY, 2005, 10 : A38 - A38
12345